| Literature DB >> 35194849 |
Tom Biénès1,2, Rodolfo Oliveira Leal1,3,4, Marina Domínguez-Ruiz1,5, Rodolfo Elvas De Carvalho1, Nina Fernandes Rodrigues1,2, Claire Dally6, Jean-Charles Husson6, Kevin Le Boedec1, Juan Hernandez1,7.
Abstract
BACKGROUND: The relationships among gastric lymphoid follicular hyperplasia (GLFH), Helicobacter-like organisms (HLOs), and clinical signs have not been established in dogs.Entities:
Keywords: Helicobacter; bacterial; bacterial species; chronic gastritis; dog; gastric follicular hyperplasia; gastroenterology; microbiology
Mesh:
Year: 2022 PMID: 35194849 PMCID: PMC8965270 DOI: 10.1111/jvim.16387
Source DB: PubMed Journal: J Vet Intern Med ISSN: 0891-6640 Impact factor: 3.333
FIGURE 1Histopathological scoring of lymphofollicular hyperplasia (LFH) of HES‐stained gastric biopsies. (A) normal, small lymphoid aggregates or follicles occupying <10% of the biopsy area, (B) mild LFH, mild hyperplasia with lymphoid aggregates or follicles occupying 10%‐30% of the biopsy area, (C) moderate LFH, lymphoid aggregates or follicles occupying 30%‐50% of the biopsy area, and (D) marked LFH, lymphoid aggregates or follicles occupying >50% of the biopsy area
Study group characteristics
| Group | n | Median age (years; min‐max) | Sex |
|---|---|---|---|
| 1: French Bulldogs | 63 | 2 (10‐10 months) | 47 IM, 3 CM, 9 IF, 4 SF |
| 2: Non‐FB brachycephalic dogs | 45 | 4 (10‐11 months) | 22 IM, 3 CM, 11 IF, 9 SF |
| 3: Control group | 180 | 7 (10‐15 months) | 74 IM, 13 CM, 44 IF, 48 SF |
Abbreviations: CM, castrated males; IF, intact females; IM, intact males; SF, spayed females.
Univariate mixed‐effect ordered logistic regression models of signalment and clinical independent variables associated with GLFH severity
| Variable | % (total n/N‐GLFH) | % (n/N‐Non‐GLFH) | Odds ratio (95% CI) |
|
|---|---|---|---|---|
| Intact female | 61 (39/64) | 39 (25/64) | 1.0 | |
| Neutered female | 53 (33/61) | 47 (28/61) | 0.41 (0.11‐1.49) | .18 |
| Intact male | 47 (67/143) | 53 (76/143) | 0.28 (0.08‐0.91) | .04 |
| Neutered male | 53 (10/19) | 9 (9/19) | 0.32 (0.01‐5.23) | .45 |
| Vomiting | 55 (80/138) | 45 (68/150) | 3.36 (1.15‐3.78) | .03 |
| Regurgitation | 22 (30/138) | 14 (21/150) | 1.52 (0‐35‐6.53) | .58 |
| Diarrhea | 23 (32/138) | 44 (66/150) | 0.74 (0.23‐2.29) | .6 |
| Cough | 6 (8/138) | 9 (13/150) | 0.31 (0.04‐2.01) | .22 |
| Respiratory distress | 22 (30/138) | 18 (27/150) | 1.83 (0.34‐9.50) | .48 |
| Dysphagia | 18 (25/138) | 25 (37/150) | 0.72 (0.14‐3.50) | .69 |
| Group 1: French Bulldogs | 60 (38/63) | 40 (25/63) | 3.81 (1.0‐13.53) | .04 |
| Group 2: Non‐FB brachycephalic dogs | 46 (21/45) | 53 (24/45) | 3.14 (0.53‐18.59) | .21 |
| Group 3: Control group | 44 (80/180) | 56 (100/180) | 1.0 |
Abbreviations: GLFH, gastric lymphofollicular hyperplasia; HLOs, Helicobacter‐like organisms; N, GLFH; total population with GLFH; n/N‐Non‐GLFH: percentage of dogs with the variable and without GLFH in all dogs free of GLFH Total n/N‐GLFH: percentage of dogs with the variable and GLFH in all dogs with GLFH.
Reference category: intact females.
Reference category: control group.
Univariate mixed‐effect ordered logistic regression models of independent histopathological variables associated with GLFH severity
| Variables | Grade | % total n/N‐GLFH | % n/N‐Non‐GLFH | Odds ratio (CI 95%) |
|
|---|---|---|---|---|---|
| Surface injury | 0 | 48 (67/138) | 47 (71/150) | 1.0 | |
| 1 | 32 (44/138) | 29 (42/150) | 0.65 (0.26‐1.59) | .35 | |
| 2 | 17 (23/138) | 17 (26/150) | 0.81 (0.24‐2.68) | .73 | |
| 3 | 3 (4/138) | 7 (11/150) | 0.16 (0.01‐2.34) | .18 | |
| Gastric pit injury | 0 | 57 (80/138) | 56 (86/150) | 1.0 | |
| 1 | 31 (42/138) | 29 (43/150) | 0.57 (0.24‐1.29) | .18 | |
| 2 | 9 (13/138) | 9 (13/150) | 0.80 (0.22‐2.84) | .73 | |
| 3 | 2 (3/138) | 5 (8/150) | 0.13 (0.01‐2.09) | .15 | |
| Gastric fibrosis atrophy | 0 | 55 (77/138) | 51 (77/150) | 1.0 | |
| 1 | 24 (34/138) | 34 (52/150) | 0.87 (0.037‐2.01) | .75 | |
| 2 | 18 (26/138) | 13 (19/150) | 0.53 (0.17‐1.63) | .27 | |
| 3 | 2 (2/138) | 2 (2.4/150) | 0.58 (0.057‐5.82) | .64 | |
| Gastric intraepithelial lymphocyte | 0 | 55 (76/138) | 49 (73/150) | 1.0 | |
| 1 | 38 (53/138) | 46 (70/150) | 0.06 (0.01‐0.41) | .004 | |
| 2 | 5 (7/138) | 4 (6/150) | 0.47 (0.03‐5.97) | .56 | |
| 3 | 1 (2/138) | 1 (1/150) | 3.03 (0.04‐191.19) | .6 | |
| Gastric lamina propria lymphocytes | 0 | 4 (6/138) | 15 (22/150) | 1.0 | |
| 1 | 44 (75/138) | 48 (71/150) | 3.23 (0.94‐11.10) | .06 | |
| 2 | 45 (62/138) | 32 (49/150) | 10.68 (3.09‐36.86) | <.001 | |
| 3 | 7 (10/138) | 5 (8/138) | 71.36 (8.65‐588.46) | <.001 | |
| Gastric lamina propria eosinophils | 0 | 91 (127/138) | 87 (131/150) | 1.0 | |
| 1 | 6 (8/138) | 10 (14/150) | 1.57 (0.033‐7.44) | .57 | |
| 2 | 2 (4/138) | 2 (4/150) | 1.42 (0.09‐21.50) | .8 | |
| 3 | 0 (0/138) | 1 (1/150) | 0.01 (0) | 1.0 | |
| Gastric lamina propria neutrophils | 0 | 86 (118/138) | 84 (126/150) | 1.0 | |
| 1 | 14 (20/138) | 16 (24/150) | 0.27 (0.01‐5.93) | .63 | |
| 2 | 0 (0/138) | 0 (0/138) | 0.01 (0) | 1.0 | |
|
| 0 | 34 (48/138) | 48 (73/150) | 1.0 | |
| 1 | 26 (36/138) | 18 (28/150) | 7.88 (2.66‐23.25) | <.001 | |
| 2 | 22 (31/138) | 16 (25/150) | 5.71 (1.38‐23.58) | .02 | |
| 3 | 17 (23/138) | 9 (14/150) | 21.66 (2.30‐203.97) | .01 | |
| Duodenal villus stunting | 0 | 82 (114/138) | 78 (116/150) | 1.0 | |
| 1 | 13 (18/138) | 18 (27/150) | 0.58 (0.13‐2.52) | .5 | |
| 2 | 4 (8/138) | 3 (5/150) | 1.49 (0.06‐32.74) | .8 | |
| 3 | 0 (0/138) | 1 (2/150) | 0.01 (0) | 1.0 | |
| 0 | 92 (127/138) | 83 (125/150) | 1.0 | ||
| Duodenal epithelial injury | 1 | 8 (11/138) | 11 (17/150) | 0.14 (0.02‐0.91) | .04 |
| 2 | 5 (6/138) | 4 (6/150) | 0.19 (0.13‐2.64) | .2 | |
| 3 | 1 (2/138) | 2 (3/150) | 0.43 (0.01‐16.09) | .65 | |
| Duodenal crypt distension | 0 | 88 (122/138) | 87 (131/150) | 1.0 | |
| 1 | 9 (12/138) | 9 (13/150) | 0.34 (0.06‐1.90) | .22 | |
| 2 | 2 (3/138) | 3 (4/150) | 0.27 (0.01‐5.82) | .4 | |
| 3 | 1 (1/138) | 1 (1/50) | 0.04 (0.01‐3.66) | .16 | |
| Duodenal lacteal distension | 0 | 68 (94/138) | 66 (99/150) | 1.0 | |
| 1 | 22 (30/138) | 18 (27/150) | 0.85 (0.25‐2.85) | .8 | |
| 2 | 10 (14/138) | 8 (12/150) | 0.66 (0.12‐3.43) | .62 | |
| 3 | 1 (1/138) | 0 (0/150) | 0.76 (0.01‐1972.48) | .94 | |
| Duodenal fibrosis | 0 | 90 (125/138) | 88 (133/150) | ||
| 1 | 8 (11/138) | 7 (11/150) | 0.98 (0.17‐5.66) | .98 | |
| 2 | 1 (2/138) | 1 (2/150) | 0.3 (0.01‐15.38) | .55 | |
| 3 | 1 (1/138) | 1 (1/150) | 0.07 (0.01‐18.21) | .34 | |
| Duodenal intraepithelial lymphocytes | 0 | 88 (120/138) | 89 (134/150) | 1.0 | |
| 1 | 6 (8/138) | 9 (14/150) | 0.15 (0.01‐1.10) | .06 | |
| 2 | 2 (3/138) | 2 (3/150) | 1.41 (0.01‐138.52) | .88 | |
| 3 | 0 (0/138) | 0 (0/150) | 0.01 (0) | 1.0 | |
| Duodenal lamina propria lympocytes | 0 | 20 (29/138) | 33 (50/150) | 0.1 | |
| 1 | 22 (41/138) | 19 (28/150) | 0.96 (0.01‐4.60) | .95 | |
| 2 | 51 (70/138) | 42 (63/150) | 1.21 (0.28‐5.06) | .8 | |
| 3 | 8 (12/138) | 6 (9/150) | 0.83 (0.57‐12.16) | .9 | |
| Duodenal lamina propria eosinophils | 0 | 90 (125/138) | 89 (135/150) | 1.0 | |
| 1 | 7 (9/138) | 8 (12/150) | 0.46 (0.07‐2.80) | .4 | |
| 2 | 2 (3/138) | 2 (2/150) | 0.21 (0.08‐5.44) | .35 | |
| 3 | 1 (1/138) | 1 (1/150) | 0.28 (0.01‐134.54) | .69 | |
| Duodenal lamina propria neutrophils | 0 | 82 (113/138) | 86 (129/150) | 1.0 | |
| 1 | 15 (20/138) | 11 (15/150) | 0.05 (0.01‐0.50) | .85 | |
| 2 | 3 (4/138) | 2 (3/150) | 2.94 (2.16‐3.70) | .46 | |
| 3 | 0 (0/138) | 1 (1/150) | 6.36 (5.35‐7.91) | .25 |
Abbreviations: CI, confidence interval; GLFH, gastric lymphofollicular hyperplasia; N, GLFH; total population with GLFH; n/N‐Non‐GLFH, percentage of dogs with the variable and without GLFH in all dogs free of GLFH; Total n/N‐GLFH, percentage of dogs with the variable and GLFH in all dogs with GLFH.
Reference category.
FIGURE 2Predictive margins of the probability of each HLO score (on the y‐axis) depending on the age of the dog (on the x‐axis). The predicted probability of an HLO score of 0 was much lower in a 1‐year‐old dog (.37) than in a 15‐year‐old dog (.78). Error bars represent 95% confidence intervals. HLOs, Helicobacter‐like organisms
FIGURE 3Comparison of HLO scores among the 3 groups. The FB breed showed the highest HLOs score comparing to non‐French Bulldog brachycephalic dogs and control group (P < .001, confidence interval 95%). The line represents the median HLOs score for each group. Control group (CG) had a median of 0. Boxes represent the minimum and maximum score for each group. Score 0 = no HLOs observed, 1 = few organisms observed (1‐20 organisms per field), 2 = moderate number of HLOs observed (from 21 to 100 organisms per field), and 3 = high number of HLOs observed (>100 organisms per field). CG: control group; FB, French Bulldog; HLOs, Helicobacter‐like organisms; Non‐FB, non‐French Bulldog brachycephalic dogs
FIGURE 4Positive association between the GLFH grade and the presence of HLOs. Positive association between the GLFH grade and the presence of HLOs in the global population (P < .001). GLFH, gastric lymphofollicular hyperplasia; HLOs, Helicobacter‐like organisms. Error bars represent 95% confidence intervals
Multivariate mixed‐effect ordered logistic regression of variables associated with GLFH
| Variables | Group/grade | Total n/N‐GLFH (%) | n/N‐Non‐GLFH (%) | Odds ratio (CI 95%) |
|
|---|---|---|---|---|---|
| Breed | 1 | 60 (38/63) | 40 (25/63) | 1.22 (0.33‐4.42) | .76 |
| 2 | 45 (21/45) | 54 (24/45) | 1.75 (0.28‐10.83) | .55 | |
| 3 | 44 (80/180) | 56 (100/180) | |||
| Age | 0.89 (0.77‐1.02) | .11 | |||
| Vomiting | 1 | 55 (80/138) | 45 (68/150) | 4 (1.37‐11.70) | .01 |
| HLO | 0 | 34 (48/138) | 48 (73/150) | 1.0 | |
| 1 | 26 (36/138) | 18 (28/150) | 5.87 (2.22‐15.52) | <.001 | |
| 2 | 22 (31/138) | 16 (25/150) | 5.99 (2.07‐17.29) | <.001 | |
| 3 | 17 (23/138) | 9 (14/150) | 16.71 (4.36‐63.91) | <.001 |
Abbreviations: CI, confidence interval; FB, French Bulldog; GLFH, gastric lymphofollicular hyperplasia; Group 1, French Bulldogs; Group 2, non‐FB brachycephalic dogs; Group 3, control group; HLOs, Helicobacter‐like organisms; N, GLFH; total population with GLFH; n/N‐Non‐GLFH: percentage of dogs with the variable and without GLFH in all dogs free of GLFH; Total n/N‐GLFH: percentage of dogs with the variable and GLFH in all dogs with GLFH.
Reference category.